INST 0603C Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2009 by University of New Mexico.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
University of New Mexico
ClinicalTrials.gov Identifier:
NCT00322712
First received: May 5, 2006
Last updated: June 23, 2010
Last verified: March 2009
  Purpose

Chart Review of patients with pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.


Condition
Pancreatic Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: INST 0603C Chart Review on Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer

Resource links provided by NLM:


Further study details as provided by University of New Mexico:

Estimated Enrollment: 20
Study Start Date: February 2006
Estimated Study Completion Date: February 2011
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Detailed Description:

Chart Review to describe the clinical outcomes in patients pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with unresectable/metastatic pancreatic cancer treated in the UNM Cancer Research and Treatment Center.

Criteria

Inclusion Criteria:

Patients with unresectable/metastatic pancreatic cancer treated in the UNM Cancer Research and Treatment Center.

Exclusion Criteria:

Not specified.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00322712

Locations
United States, New Mexico
University of New Mexico
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
Investigators
Principal Investigator: Fa-Chyi Lee, MD University of New Mexico
  More Information

No publications provided

Responsible Party: Fa-Chyi Lee, MD; Principal Investigator, University of New Mexico - CRTC
ClinicalTrials.gov Identifier: NCT00322712     History of Changes
Other Study ID Numbers: INST 0603C
Study First Received: May 5, 2006
Last Updated: June 23, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms
Neoplasms by Site
Pancreatic Diseases

ClinicalTrials.gov processed this record on October 21, 2014